The Ritedose Corporation Announces Revolutionary Liquid Med Dispenser <br><em>SuredoseRx™ to launch in first quarter</em>

COLUMBIA, S.C. (January 18) — The Ritedose Corporation has announced the development of and plans to commercialize the first new way to dispense single-dose liquid medications in two decades. After five years of R&D, the Columbia-based developer of blow-fill-seal unit dose technology is launching SuredoseRx™, an easier and more convenient

Continue reading

Ritedose Pharmaceuticals Launches Cromolyn Sodium Oral Solution (Concentrate) 100 mg/5 ml

COLUMBIA, S.C. (January 5, 2022) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product, Cromolyn Sodium Oral Solution (Concentrate), 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a

Continue reading

Novo Holdings to acquire Ritedose: <br><em>Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell.</em>

COPENHAGEN, Denmark, Jan. 4, 2022 /PRNewswire/ – Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory drugs, and vaccines.

Continue reading

Ritedose Pharmaceuticals Launches Budesonide Inhalation Suspension (0.5 mg/2 ml)

COLUMBIA, S.C. (December 29, 2021) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose generic product for hospitals, Budesonide Inhalation Suspension (0.5 mg/2 ml). It is the first of five new inhalation products scheduled for release by March 2022. Ritedose Pharmaceuticals is a

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)</em>

COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)</em>

COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Sodium Chloride Injection 23.4% (120mEq/30 mL)</em>

COLUMBIA, S.C. (August 11, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Sodium Chloride Injection 23.4% (120mEq/30 mL). It is the 10th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a division

Continue reading

Ritedose Efficiency Innovation Yields Up to 25% Increase in CDMO Production Capability

Engineering for Surge Development Columbia, SC – The Ritedose Corporation, the company born from the inventors of Blow-Fill-Seal (BFS) technology, has implemented engineering innovations that will now allow the country’s leading BFS Contract Development and Manufacturing Organization (CDMO) to increase its production capacity by up to 25% over industry standards.

Continue reading

Ritedose Releases Two New Single-Dose Syringe Products for Hospital Pharmacies: <em>Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL)</em>

COLUMBIA, S.C. (May 21, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, launched two new unit dose syringe products, Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL). These are part of a six-month, 12-product rollout from Ritedose for

Continue reading

Ritedose Brings New Unit Dose Syringe Product to the Market: <em>Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL)</em>

COLUMBIA, S.C. (May 14, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Succinylcholine Chloride Injection 100 mg/5 mL (20 mg/mL). It is part of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a

Continue reading